In Vivo Engineering of Cells Using Targeted Lipid Nanoparticles

Time: 2:45 pm
day: Conference Day Two


  • Capstan’s novel targeted LNP (tLNP) platform purpose-built for preferential delivery of RNA to target cells
  • tLNP platform enables two distinct approaches in vivo: direct engineering of immune cells and targeting pathogenic cells
  • Versatility of this non-viral, redosable and scalable platform allows for in vivo RNA-based therapies across broad range of diseases